Reuters logo
BRIEF-Cellular Biomedicine says Allojoin Phase I trial to be completed by Q3 2017
December 9, 2016 / 1:17 PM / a year ago

BRIEF-Cellular Biomedicine says Allojoin Phase I trial to be completed by Q3 2017

Dec 9 (Reuters) - Cellular Biomedicine Group Inc :

* Cellular Biomedicine Group Inc - trial is on schedule to be completed by Q3 of 2017

* Says interim analysis of trial has preliminarily demonstrated a safety and tolerability profile of Allojoin in three doses tested

* Cellular Biomedicine Group announces three-month interim safety data from Phase I clinical trial for Allojoin off-the-shelf allogeneic stem cell therapy for knee osteoarthritis Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below